Targeting novel biology in the tumor microenvironment
Genagon Therapeutics drug development is based on discoveries of unstudied proteins and their life cycles in innate immune cells. Disrupting this interplay is a potent tool for cancer therapies. Genagon pioneered a way to target macrophages and cancer cells and by disturbing the dynamic lifecycle of proteins within the tumor microenvironment. Targeting harmful tumor-associated macrophages directly paves the way for novel ways to target and eradicate tumors with opportunities in breast cancer, lung cancer and solid tumors.
